IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

Abstract Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell lung cancers (NSCLCs), however, are limited. Methods...

Full description

Bibliographic Details
Main Authors: Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, Peter Illei, Ming‐Tseh Li
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Cancer Medicine
Subjects:
cytosine deamination
IDH1
IDH2
lung cancers
parallel evolution
Online Access:https://doi.org/10.1002/cam4.3058

Internet

https://doi.org/10.1002/cam4.3058

Similar Items